Now I have a thorough understanding of the paper and can verify all reviewer claims against the actual paper content. Let me construct the final consolidated review.

## Summary

This paper evaluates small language models (SLMs; ≤3B params) and small vision-language models against larger medical-domain-adapted baselines on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). It introduces a "collapse analysis" across model size within the SmolLM2 and Gemma-3 families, identifying a sharp degradation in hallucination rates and prompt robustness below ~1B parameters. It also finds that LoRA-fine-tuned small LMs can match or exceed the zero-shot/few-shot performance of large medical LMs on summarization metrics, while small VLMs still lag behind large VLMs in report generation.

## Strengths

1. **Collapse analysis identifies a meaningful safety threshold.** The multi-dimensional analysis (Table 3) across model sizes within the SmolLM2 and Gemma-3 families shows a clear non-uniform degradation pattern: hallucination rates spike from ~2–3% at 1.7B to 18–75% at 270–360M parameters, and task adherence and prompt robustness also drop sharply below ~1B. This empirically grounds the notion of a minimum viable scale for clinical deployment, which is a practically useful contribution.

2. **Systematic prompt averaging.** Section 3.1 explicitly averages results across five prompt templates and acknowledges that prompt sensitivity is an experimental variable rather than fixing a single template. This is a methodological step up from many zero-shot comparisons that use a single prompt.

3. **Clinically relevant metric (MEDCON).** The paper evaluates UMLS-based clinical concept coverage (MEDCON) alongside surface-level NLG metrics (BLEU, ROUGE-L, BERTScore), providing a domain-specific assessment of medical accuracy that is often missing from summarization evaluations.

4. **Multi-family, multi-scale evaluation.** The comparison spans three small LM families (SmolLM2, Gemma 3, LLaMA 3.2) and four VLM families, tested under zero-shot, few-shot, and multiple PEFT methods, giving reasonable breadth to the empirical study.

5. **Contrasting finding for VLMs.** The result that small VLMs still lag behind large VLMs after fine-tuning (Table 4) provides a useful negative result, showing that the "small model sufficiency" finding does not transfer to vision-language tasks — this nuance is valuable for practitioners.

## Weaknesses

### Fatal
None.

### Major

1. **Asymmetric comparison undermines the headline claim.** The paper's central finding — that small LMs "match or exceed" much larger medical LMs — compares *fine-tuned* small models (via LoRA/QLoRA) against *non-fine-tuned* large models used in zero- or few-shot settings. Figure 3 makes this visible (large models have no LoRA bars), and Section 3.2 states that PEFT was applied only to small LLMs. However, the abstract ("small models not only reach but occasionally exceed the performance of much larger medical LLMs"), the results section ("After LoRA fine-tuning, all small LMs outperformed large LMs across every metric"), and the discussion repeatedly state the claim without this crucial caveat. The large medical models could plausibly benefit from the same fine-tuning, so the headline comparison is not a controlled test of capacity or architecture. The paper should either (a) fine-tune all models under identical conditions, or (b) clearly re-frame the claim as "fine-tuned small LMs can match zero-shot large LMs" — a practically useful but much weaker statement — and adjust all language accordingly.

2. **Collapse analysis metrics are undefined, making the framework non-reproducible.** Table 3 reports Task Adherence, Hallucination Rate, Clinical Concept Recall, Prompt Robustness, and a composite Readiness Score, but the paper never specifies how any of these are computed. Are they automatic metrics (and if so, what are the exact operational definitions?) or human ratings? Without this information, the central "collapse analysis" — which the paper itself highlights as a key contribution — cannot be evaluated, reproduced, or trusted. For a paper that frames safety as a key concern, leaving hallucination rate undefined is a significant omission.

3. **VLM comparison also asymmetric and unclear.** Table 4 compares fine-tuned small VLMs (Florence 2, Qwen2.5-VL) against Med-Flamingo and LLaVA-Med, but the paper does not state whether these large VLMs were also fine-tuned on the MIMIC-CXR training data or evaluated zero-shot. The natural reading (bolstered by the "Fine-tuned" label on small but not large models) is that large VLMs were not fine-tuned. This weakens Finding 2: the result that "small VLMs lag behind large VLMs" is less informative when the large models have not received equivalent task-specific adaptation. The paper should clarify the evaluation protocol for the large VLM baselines.

### Minor

1. **No variance or confidence intervals.** All results are reported as point estimates on 250 test samples (Tables 2, 4) without any measure of variance. Given the known sensitivity of small models to prompt variation and stochastic decoding, the absence of error bars makes it difficult to assess whether observed differences (especially the small-margin comparisons in Table 2) are reliable.

2. **Model naming inconsistency.** Table 3 lists "SmolLM3-3B" but the paper otherwise discusses the SmolLM2 family (Table 1, Section 3.1). There is no SmolLM3 introduced or described. This appears to be an error that should be corrected, and the inclusion/exclusion of this model should be clarified.

3. **"MeQ-Small corpus" appears to be a typo.** Section 4 (Results) refers to "MeQ-Small corpus"; the correct name used elsewhere is MeQSum. This should be corrected for consistency.

4. **Fine-tuning hyperparameters for vision models are not specified.** Section 3.3 states that small VLMs were fine-tuned on 10k image–report pairs but does not report learning rate, LoRA rank, number of epochs, batch size, or other hyperparameters needed for reproducibility.

### Trivial
- The introduction mentions "models with only a few million parameters" but the smallest evaluated model is 135M; this numeric framing is slightly off.
- Table 2 reports BERTScore values in the range 0.76–0.90, while Figure 3 shows BERTScore percentages in the 52–95% range; these appear to be different scales (cosine similarity vs. percentage) and should be harmonized across the paper.

## Nice-to-Haves

- If the collapse analysis metrics were validated against expert human judgment for a subset of outputs, the safety conclusions would be substantially stronger.
- Comparison with large models under the *same* fine-tuning regime (even for a subset) would directly address the asymmetry concern and strengthen the paper's contribution.

## Removed Points

The following points from the inputs were removed with justification:

- **Criticism about MeerKAT-8B discussion being "tangential" in Related Work:** Not a substantive weakness; the section discusses relevant scaling comparisons in the literature. Removed as a nitpick that does not affect the paper's contribution.
- **Several minor section-by-section notes** (e.g., that the abstract overstates evidence, that the introduction has a numeric mismatch about "few million parameters") — these are superseded by the major weaknesses above and are better captured as framing issues in the main weaknesses or trivial items.
- **Strength Finder's claim that "Figure 3 directly contrasts ICL vs LoRA for both small and large models"** — this is factually incorrect; large models in Figure 3 have only ICL bars and no LoRA bars. Removed as inaccurate.
- **Strength Finder's strength about "LoRA fine-tuned small LMs outperform much larger medical LMs"** — while this is what the paper claims, it conflates the asymmetric comparison into a strength. Merged into the major weakness above rather than kept as a standalone strength.
- **Harsh critic's request for user studies / human evaluation:** Not standard for this type of empirical scaling study; a reasonable suggestion but not a valid weakness.
- **Harsh critic's note that Table 3 "SmolLM3" naming is inconsistent with "SmolLM2":** Kept as a minor weakness (model naming inconsistency) rather than treated as a more serious error.
- **Harsh critic's request for larger dataset or more models:** Scope creep; the paper is already reasonably broad. Moved to nice-to-have.

## Novel Insights

None beyond the paper's own contributions. The most informative observation from the cross-review is that the paper's main claimed contribution (small LMs matching large LMs) is supported by an asymmetric experimental design that the paper does not adequately acknowledge, while its potentially stronger contribution (the collapse analysis) is presented without methodological rigor. The paper would be strengthened by refocusing on the collapse analysis with properly defined metrics and reframing the fine-tuning comparison as the practically-motivated but weaker claim that it actually supports.

## Suggestions

1. **Re-frame the headline claims.** Clearly state throughout that the comparison is between *fine-tuned* small models and *non-fine-tuned* large models, or better yet, add an experiment fine-tuning the large models for a subset of the comparison to validate the finding.
2. **Define the collapse analysis metrics completely.** Provide precise operational definitions for Task Adherence, Hallucination Rate, Clinical Concept Recall, Prompt Robustness, and the Readiness Score. If they are automatic, specify the algorithm; if human-rated, describe the annotation protocol and inter-annotator agreement.
3. **Clarify the VLM evaluation protocol.** State explicitly whether Med-Flamingo and LLaVA-Med were used zero-shot, few-shot, or fine-tuned, and report the relevant setting in Table 4.
4. **Add confidence intervals or variance estimates** (e.g., bootstrap CIs or standard deviations across decoding seeds) to all tables with key comparisons.
5. **Fix the SmolLM3/MeQ-Small/scale inconsistencies** identified in the minor and trivial weaknesses.

## Score and Decision

This paper tackles a practically important question and contains useful empirical observations, particularly the collapse analysis and the VLM negative result. However, the asymmetric experimental design for the main claim coupled with undefined key metrics for the collapse analysis represent significant methodological gaps that prevent the paper from providing reliable evidence for its conclusions as currently written. Major revisions addressing the comparison asymmetry and the metric definitions could transform this into a solid contribution.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>